Business context and reporting period
This is Ventrus BioSciences, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2012. The request metadata names Assembly Biosciences, Inc.; the filing itself identifies the registrant as Ventrus BioSciences, Inc., so the company identity should be verified. Ventrus is a development-stage specialty pharmaceutical company focused on gastrointestinal conditions and reported no product revenue.
Financial results and position
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development | $4.19 million | $3.67 million | $16.77 million | $7.74 million |
| General and administrative | $1.18 million | $1.88 million | $4.27 million | $7.38 million |
| Net loss | $5.36 million | $5.80 million | $21.00 million | $15.49 million |
| Net loss per share | $0.41 | $0.50 | $1.66 | $1.79 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $18.31 million | $8.74 million |
At September 30, 2012, cash and cash equivalents were $23.56 million, total current assets were $23.67 million, current liabilities were $2.68 million, and stockholders’ equity was $21.00 million. The company reported no outstanding loans during the first nine months of 2012. No meaningful operating margin is available because the company had no product revenue and incurred operating losses.
Material changes versus the prior comparable period
- Nine-month R&D expense rose 117% year over year, primarily reflecting clinical development of VEN 309 and VEN 307-related manufacturing and trial preparation. Q3 R&D increased 14%.
- Nine-month G&A expense fell 44%, mainly due to lower stock-option and warrant expense, lower investor-relations costs, and certain salaries being reclassified to R&D. Q3 G&A declined 37%.
- Nine-month net loss widened by approximately $5.51 million, while Q3 net loss narrowed by approximately $0.45 million.
- Cash declined $13.42 million from year-end 2011. Financing provided $4.90 million in the first nine months, including $4.17 million net from at-the-market share sales and proceeds from option and warrant exercises.
Outlook, risks, and significant items
- VEN 307 (topical diltiazem for anal fissures): An earlier Phase III trial met its endpoints, but the FDA pre-NDA meeting indicated that a second Phase III trial was needed to support a planned NDA. The company said the trial began in Q4 2012, expected completion in Q4 2013, and anticipated an NDA filing in Q4 2013 if results were positive. These are forward-looking expectations, not reported outcomes.
- VEN 309 (iferanserin for hemorrhoids): Its Phase III trial did not meet endpoints. Ventrus ceased development activity in June 2012 except for winding down the program and redirected resources toward VEN 307.
- VEN 308 (phenylephrine for fecal incontinence): Further development was subject to available resources.
- Management expected existing cash to fund operations and planned development through Q2 2014. It estimated approximately $20 million to complete the VEN 307 clinical process and commercialization effort, while noting cost and timing could change materially. The filing also identifies an estimated $12 million for the second Phase III trial, $2.1 million for regulatory fees and consultants, and additional license-related payments.
- Ventrus expected continuing losses and no product revenue for at least several years. It may need additional equity, debt, collaboration, or licensing funding; such funding might not be available on acceptable terms and could dilute shareholders or require relinquishing product rights. Approximately $95.5 million remained available under its shelf registration, including about $15.5 million for the ATM program.
- Other items: the Chief Business Officer resigned effective September 30, 2012. A $125,000 license milestone payment to S.L.A. Pharma was made on October 9, 2012, after quarter-end. Cash balances at times exceeded federally insured limits. Management reported disclosure controls were effective and no material third-quarter change in internal control over financial reporting.
Investor verification priorities
- Confirm whether this Ventrus filing is the intended filing, given the Assembly Biosciences metadata mismatch.
- Verify the second VEN 307 Phase III trial’s actual start, enrollment, results, and regulatory timetable against the stated expectations.
- Assess cash burn and remaining runway against the Q2 2014 estimate, including clinical-trial and license obligations.
- Confirm current financing capacity and potential dilution or other terms if additional capital is required.
- Review the consequences of discontinuing VEN 309 and the status and resourcing of VEN 308.